Eisai’s anti-cancer agent LENVIMA receives orphan drug designation
Eisai’s anti-cancer agent LENVIMA receives orphan drug designation Japanese pharmaceutical company Eisai has received orphan drug designation for its anti-cancer agent LENVIMA with a prospective indication for uterine body cancer. LENVIMA, which obtained the designation from the Ministry of Health, Labour and Welfare (MHLW), is an orally available multiple receptor kinase inhibitor discovered by Eisai. […]
Read More